Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...